Compositions and methods for treating pancreatitis
AssigneeAnji Pharmaceuticals Inc.
InventorsCharles D. Meyers, Brian K. Hubbard, Michael H. Serrano-Wu
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods related to inhibiting or treating pancreatitis in a subject in need thereof, which include the use of a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor. The disclosed PCSK9 inhibitors and compositions including them can be used for treatment, inhibition, or prevention of pancreatitis in a subject. Treatment methods can include administering to the subject a therapeutically effective amount of a PCSK9 inhibitor.
Claims6
A method of treating acute pancreatitis or chronic pancreatitis in a subject in need thereof, the method comprising administering to the subject a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor, wherein the acute pancreatitis is not caused by an infection,
- wherein the PCSK9 inhibitor is AMG145 (Evolocumab), 1D05-IgG2, SAR236553/REGN727 (Alirocumab), RN-316 (Bococizumab), LGT209, LY3015014 (Frovocimab), or RG7652.
A method of treating acute pancreatitis or chronic pancreatitis in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor, wherein the acute pancreatitis is not caused by an infection,
- wherein the PCSK9 inhibitor is AMG145 (Evolocumab), 1D05-IgG2, SAR236553/REGN727 (Alirocumab), RN-316 (Bococizumab), LGT209, LY3015014 (Frovocimab), or RG7652.
Dependencies are inferred from the claim text.